This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree Preview

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

List of authors.
  • Pasi A. Jänne, M.D., Ph.D.,
  • Gregory J. Riely, M.D., Ph.D.,
  • Shirish M. Gadgeel, M.D.,
  • Rebecca S. Heist, M.D., M.P.H.,
  • Sai-Hong I. Ou, M.D., Ph.D.,
  • Jose M. Pacheco, M.D.,
  • Melissa L. Johnson, M.D.,
  • Joshua K. Sabari, M.D.,
  • Konstantinos Leventakos, M.D., Ph.D.,
  • Edwin Yau, M.D., Ph.D.,
  • Lyudmila Bazhenova, M.D.,
  • Marcelo V. Negrao, M.D.,
  • Nathan A. Pennell, M.D., Ph.D.,
  • Jun Zhang, M.D., Ph.D.,
  • Kenna Anderes, Ph.D.,
  • Hirak Der-Torossian, M.D.,
  • Thian Kheoh, Ph.D.,
  • Karen Velastegui, B.Sc.,
  • Xiaohong Yan, Ph.D.,
  • James G. Christensen, Ph.D.,
  • Richard C. Chao, M.D.,
  • and Alexander I. Spira, M.D., Ph.D.

Abstract

Background

Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1–1b part of the KRYSTAL-1 phase 1–2 study.

Methods

Download a PDF of the Research Summary.

In a registrational phase 2 cohort, we evaluated adagrasib (600 mg orally twice daily) in patients with KRASG12C-mutated non–small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti–programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety.

Results

As of October 15, 2021, a total of 116 patients with KRASG12C-mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients — grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) — and resulted in drug discontinuation in 6.9% of patients.

Conclusions

In patients with previously treated KRASG12C-mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.)

Digital Object ThumbnailQUICK TAKE VIDEO SUMMARY
Adagrasib in KRASG12C-Mutated Lung Cancer
 02:07

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Supported by Mirati Therapeutics.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

This article was published on June 3, 2022, at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the participating patients and their families and the clinical study teams, and Alex Coulthard of Ashfield MedComms, an Ashfield Health company, for medical writing assistance, funded by Mirati Therapeutics.

Author Affiliations

From the Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) — both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) — all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) — all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at Tennessee Oncology, Nashville (M.L.J.); the Department of Oncology, Mayo Clinic, Rochester, MN (K.L.); the University of Texas M.D. Anderson Cancer Center, Houston (M.V.N.) and US Oncology Research, The Woodlands (A.I.S.) — both in Texas; Cleveland Clinic Taussig Cancer Institute, Cleveland (N.A.P.); the Division of Medical Oncology, Department of Internal Medicine, and the Department of Cancer Biology, University of Kansas Medical Center, Kansas City (J.Z.); and Virginia Cancer Specialists and NEXT Oncology Virginia — both in Fairfax (A.I.S.).

Dr. Jänne can be contacted at or at the Dana–Farber Cancer Institute, 450 Brookline Ave., LC4114, Boston, MA 02215.

A list of the investigators in the KRYSTAL-1 study is provided in the Supplementary Appendix, available at NEJM.org.

Print Subscriber? Activate your online access.